<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609375</url>
  </required_header>
  <id_info>
    <org_study_id>Universidad Javeriana</org_study_id>
    <nct_id>NCT00609375</nct_id>
  </id_info>
  <brief_title>Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen</brief_title>
  <acronym>CEFPK/PD</acronym>
  <official_title>Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen in Adult Critically Ill Patients With Gram Negative Bacilli Bacteremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javeriana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Simon Bolivar, Bogota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Palermo, Bogota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Santa Clara, Bogota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación San Carlos, Bogota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital san Juan de Dios, Antioquia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital san Jorge, Pereira</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Javeriana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous
      infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in
      Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate
      of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and
      rates of relapse after 28 days.

      Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or
      microbiological cure greater than the intermittent administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate global mortality rate</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to evaluate clinical and/or microbiologic relapses</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate clinical and bacteriological response</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate clinical and bacteriological response</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate clinical and bacteriological response</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sepsis</condition>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of cefepime in continuous infusion (3 Gr over 24 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime</intervention_name>
    <description>Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>maxipime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime</intervention_name>
    <description>Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Maxipime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with sepsis, severe sepsis o septic shock diagnosis hospitalized in Intensive
             care Unit.

          -  Presence or suspect of Gram negative bacilli bacteremia

          -  To be possible the follow up according to planned visits

          -  Patients should be venous access to administrate the antibiotic

          -  Patients, whom the physicians consider cefepime like election treatment

        Exclusion Criteria:

          -  Patients with a high degree of immunosuppression defined by:

               -  The presence of neutropenia (Neutrophils count less than 500 cells/mL, or
                  Infection with HIV-AIDS with count of less than 50 CD4 cells/mL, or chronic
                  Administration of immunosuppressive drugs (prednisone more than 5 mg/per day,
                  azathioprine, cyclophosphamide, mycophenolate mofetil, etc.)

          -  Patients with chronic renal failure.

          -  Pregnant female patients

          -  Patients in whom to approach the doctor is considered with a high probability of dying
             in the next 48 hours (e.g. multiorgan system failure with more than 5 organs engaged
             according to the criteria of MarshalL et al. or shock irreversible.

          -  Patients with chronic infections as osteomyelitis or have prosthesis that would
             perpetuate the infection and requiring the administration of antibiotics for an
             extended time (including Endocarditis). -Patients with mixed infections that include
             Gram positive microorganisms or fungal infections.

          -  -Patients who have received in the past 30 days cefepime.

          -  Patients with presence of a gram negative bacillus resistant to cefepime. -Patients
             who are not able to identify them a bacillus gram negative.

          -  Patients who they are not able to confirm the antibiotic susceptibility of gram
             negative bacillus. -Patients with concomitant with antimicrobial activity for Gram
             negative bacilli (e.g. fluoroquinolones, aminoglycosides, etc.)

          -  Patients who have known hypersensitivity to B lactams or cefepime
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>carlos A Alvarez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Javeriana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvaro Ruiz, MD; MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Pontificia Universidad Javeriana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabian GIL, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Pontificia Universidad Javeriana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Rionegro</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Palermo</name>
      <address>
        <city>Bogota</city>
        <state>DC</state>
        <zip>6</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion San Carlos</name>
      <address>
        <city>Bogota</city>
        <state>DC</state>
        <zip>6</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Clara</name>
      <address>
        <city>Bogota</city>
        <state>DC</state>
        <zip>6</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Simon Bolivar</name>
      <address>
        <city>Bogota</city>
        <state>DC</state>
        <zip>6</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario san Ignacio</name>
      <address>
        <city>Bogota</city>
        <state>DC</state>
        <zip>6</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Jorge</name>
      <address>
        <city>Pareira</city>
        <state>Risaralda</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>February 6, 2008</last_update_submitted>
  <last_update_submitted_qc>February 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Carlos Arturo Alvarez</name_title>
    <organization>Medicine School, Pontificia Universidad javeriana</organization>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>Intravenous infusions</keyword>
  <keyword>cefepime</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

